Chronic Myeloid Leukemia (CML)

- **Chronic and Accelerated phase, Ph+**
  - **New diagnosis** TKI treatment-naive
  - **IRB 16941** Observational Change in cardiovascular and metabolic risks in patients with CML-CP receiving TKI first-line therapy
  - **IRB 19801** S1712 - A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease

- **Resistant to at least two prior TKI**
  - **IRB 15037** A Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
  - **IRB 15085** Phase 2 Ponatinib for Chronic Phase CML
  - **IRB 19316** Phase 2 Ruxolitinib Plus TKI for Chronic Phase CML

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php